COMPANY

AROG Pharmaceuticals

HQ: Dallas, TX source · arogpharma.com ↗

Location: Dallas, TX · source · Sep 28, 2018

Profile checked Oct 10, 2026

Keywords: Acute Myeloid Leukemia Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations Newly Diagnosed FLT3 Mutated AML FLT3-ITD Mutation FLT3/TKD Mutation PDGFR-Alpha D842V PDGFRA Gene Amplification Newly Diagnosed AML With FLT3 Activating Mutations Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations Relapsed/Refractory Acute Myeloid Leukemia (AML) Acute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior Therapies GIST With D842V Mutated PDGFRA Gene Recurrent/Refractory Glioblastoma Esophagogastric Adenocarcinoma Relapsed/Refractory FLT3-mutated AML Glioma D842-related Mutant GIST Non-Small-Cell Lung Carcinoma Crenolanib CP-868,596 Crenolanib Besylate (CP-868,596-26) Crenolanib (CP-868,596)

17Trials (company is sponsor)

Timeline

Aug 16, 2018 Trial start Phase 3: Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML source ↗
Aug 15, 2018 Trial start Phase 3: Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML source ↗
2018-01 Trial start Phase 2: A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia source ↗
Apr 14, 2017 Trial start Phase 1: Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma source ↗
2016-08 Trial start Phase 3: Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST source ↗
2016-04 Trial start Phase 2: Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification source ↗
2016-02 Trial start Phase 1/Phase 2: Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML source ↗
2015-09 Trial start Phase 1/Phase 2: Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients source ↗
2015-09 Trial start Phase 2: Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients source ↗
2015-01 Trial start Phase 2: A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations source ↗
2012-10 Trial start II: A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations source ↗
2012-07 Trial start II: Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations source ↗
2011-04 Trial start Phase 2: Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas source ↗
2011-04 Trial start Phase 2: Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene source ↗
2007-05 Trial start 2: A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel. source ↗
2005-12 Trial start Phase 1: CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors source ↗

Clinical trials (lead sponsor) 17

Record	Title	Phase	Status	Start	Primary completion
NCT03250338	Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML	Phase 3	Completed	Aug 16, 2018	Apr 3, 2026 (actual)
NCT03258931	Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML	Phase 3	Completed	Aug 15, 2018	Apr 6, 2026 (actual)
NCT03620318	Individual Patient Compassionate Use of Crenolanib	Not listed	Available	Not listed	Not listed
NCT02400281	Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients	Phase 1/Phase 2	Completed	2015-09	Jul 15, 2020 (actual)
NCT02283177	A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations	Phase 2	Completed	2015-01	2019-12 (actual)
NCT01522469	Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations	II	Completed	2012-07	2014-08 (actual)
NCT02626338	Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML	Phase 1/Phase 2	Completed	2016-02	2018-02 (actual)
NCT02400255	Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients	Phase 2	Completed	2015-09	2022-05 (actual)
NCT01657682	A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations	II	Completed	2012-10	2019-04 (actual)
NCT02847429	Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST	Phase 3	Unknown status (ClinicalTrials.gov)	2016-08	2021-08 (estimated)
NCT02626364	Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification	Phase 2	Completed	2016-04	2020-07 (actual)
NCT03193918	Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma	Phase 1	Completed	Apr 14, 2017	Jul 15, 2020 (actual)
NCT03324243	A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia	Phase 2	Withdrawn	2018-01	2020-12 (estimated)
NCT01229644	Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas	Phase 2	Terminated	2011-04	2012-06 (actual)
NCT01243346	Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene	Phase 2	Completed	2011-04	2014-07 (actual)
NCT00386555	A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.	2	Withdrawn	2007-05	Not listed
NCT00949624	CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors	Phase 1	Completed	2005-12	2008-06 (actual)